Indication

As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.

Medicine details

Medicine name:
cemiplimab (Libtayo)
SMC ID:
SMC2216
Pharmaceutical company
Sanofi
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q1 2020
SMC meeting date:
Q4 2019
Patient group submission deadline:
30 September 2019